Designing clinical trials for dystonia
Wendy R Galpern1, Christopher S Coffey, Alberto Albanese
1National Institute of Neurological Disorders and Stroke, National Institutes of Health, 6001 Executive Blvd., Rm 2225, Bethesda, MD, 20892, USA, galpernw@ninds.nih.gov.
Abstract:
With advances in the understanding of the pathophysiology of dystonia, novel therapeutics are being developed. Such therapies will require clinical investigation ranging from exploratory studies to examine safety, tolerability, dosage selection, and preliminary efficacy to confirmatory studies to evaluate efficacy definitively. As dystonia is a rare and complex disorder with clinical and etiological heterogeneity, clinical trials will require careful consideration of the trial design, including enrollment criteria, concomitant medication use, and outcome measures. Given the complexities of designing and implementing efficient clinical trials, it is important for clinicians and statisticians to collaborate closely throughout the clinical development process and that each has a basic understanding of both the clinical and statistical issues that must be addressed. To facilitate designing appropriate clinical trials in this field, we review important general clinical trial and regulatory principles, and discuss the critical components of trials with an emphasis on considerations specific to dystonia. Additionally, we discuss designs used in early exploratory, late exploratory, and confirmatory phases, including adaptive designs.
Insights
Developing novel therapeutics for dystonia requires careful clinical trial design. This includes considering rare disease complexities, statistical collaboration, and adaptive designs for efficient drug development.
Area of Science:
- Neurology
- Clinical Pharmacology
- Biostatistics
Background:
- Advances in understanding dystonia pathophysiology are driving the development of novel therapeutics.
- Dystonia is a rare, complex neurological disorder characterized by clinical and etiological heterogeneity.
Purpose of the Study:
- To review general clinical trial and regulatory principles relevant to developing dystonia therapeutics.
- To discuss critical trial design components, emphasizing considerations specific to dystonia.
- To explore trial designs for exploratory and confirmatory phases, including adaptive designs.
Main Methods:
- Review of general clinical trial and regulatory principles.
- Discussion of critical components for dystonia clinical trial design.
- Examination of trial designs across different development phases (early exploratory, late exploratory, confirmatory).
Main Results:
- Novel therapeutics for dystonia necessitate rigorous clinical investigation, from safety and dosage studies to definitive efficacy trials.
- Effective clinical trials for dystonia require careful planning regarding enrollment, concomitant medications, and outcome measures due to the disorder's complexity.
- Collaboration between clinicians and statisticians is crucial for addressing clinical and statistical challenges in dystonia drug development.
Conclusions:
- Designing efficient and appropriate clinical trials for novel dystonia therapeutics is complex.
- Consideration of trial design elements, statistical methodologies, and regulatory principles is essential.
- Adaptive designs offer potential benefits for optimizing clinical trials in rare and heterogeneous conditions like dystonia.
More Related Videos
Related Concept Videos
01:16Clinical Trials
There are four phases in a clinical trial. A phase one...
01:11Clinical Trials: Overview
01:28Preclinical Development: Overview